Both companies will work to revolutionize cell culture media in biotech and the vaccine industry with animal-free, high-yield ...

Precision Medicine Group, a provider of next-generation drug development, CRO and commercialization services, has appointed Eric Hodgins as its Chief Information and Technology Officer, overseeing all ...

Bristol Myers Squibb’s Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with ...

Parexel, a clinical research organization (CRO), has appointed Charlotte Moser, MD, PhD, MBA as Chief Medical Officer.

Wyatt McDonnell of Infinimmune shares insight on human-first models and what the FDA's policy shift means for biotech R&D.

Vanessa Zann and Andrew Parker share insights on poorly soluble APIs, approaches for modified release formulation development, and navigating accelerated approval pathways.

The CCT Tower Elite provides a singular solution for pharmaceutical companies looking to ship large consignments globally.

Cyprumed G mbH, a drug delivery company specializing in oral peptide formulations and MSD, have signed a Non-Exclusive License and Option Agreement to develop oral formulations of MSD’s peptides using ...

Meribel Pharma Solutions, a new mid-sized CDMO, has launched with an extensive integrated network across Europe.

The U.S. Food and Drug Administration has designated Celltrion Inc.’s YUFLYMA (adalimumab-aaty), as an interchangeable biosimilar to Humira.

Boehringer Ingelheim and Cue Biopharma Inc. have joined forces to develop and commercialize Cue Biopharma’s CUE-501 product candidate.

Galapagos NV, a global biotechnology company, announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025. The company expects to announce Huston’s successor in the coming ...